Defective Medical Devices in Georgia: Hip Implants, Pacemakers, and Product Liability

On this page

A metal-on-metal hip resurfaces and sheds chromium and cobalt into surrounding tissue. A pacemaker lead fractures and stops pacing. A device implanted to restore function instead requires a second surgery to remove it. In Georgia these injuries fall under ordinary product-liability law, but a federal doctrine decides many of them before a jury ever weighs the defect: whether the device cleared the FDA through full premarket approval or through the lighter 510(k) pathway can determine whether a state-law claim proceeds at all.

Where Georgia Product Law Meets a Federal Filter

A medical device is a product, and Georgia’s product-liability statute, OCGA 51-1-11, supplies the baseline. The statute imposes strict liability on a manufacturer that sells a product not merchantable and reasonably suited to its intended use, recognizing manufacturing defects, design defects, and failures to warn, and it carries a ten-year statute of repose running from the first sale of each unit, with a duty-to-warn exception that keeps a claim alive where the danger became known to the manufacturer after sale. That framework is shared across every product post and is stated here only in outline. What sets devices apart is that the federal Medical Device Amendments of 1976 can preempt state claims, so the threshold question is not only whether the device was defective but whether federal law lets a Georgia court ask.

The Premarket-Approval Bar and Riegel

The dividing line is the FDA pathway. High-risk Class III devices, including many pacemakers and certain hip systems, undergo premarket approval, the agency’s most rigorous review of a specific design and label. In Riegel v. Medtronic, 552 U.S. 312 (2008), the Supreme Court held that premarket approval imposes federal requirements that expressly preempt state-law claims seeking to impose requirements “different from, or in addition to” them, barring claims that a premarket-approved device should have been designed or labeled differently than the FDA approved. For such a device, a straight design-defect or failure-to-warn theory under OCGA 51-1-11 generally cannot proceed.

The Narrow Gap for Parallel Claims

Riegel did not close every door. A claim that a manufacturer violated the very federal requirements the FDA imposed, and that the violation also breaches a recognized state duty, is a “parallel claim” and is not preempted, because it adds nothing to federal law. A manufacturing-defect claim alleging the unit departed from its approved specifications can fit this gap. The gap is narrow on the other side as well: under Buckman Co. v. Plaintiffs’ Legal Committee, 531 U.S. 341 (2001), a claim resting solely on fraud against the FDA is impliedly preempted. A viable parallel claim must therefore track an existing Georgia tort duty and an alleged federal-requirement violation at the same time.

When 510(k) Clearance Leaves the Door Open

Lower-risk devices often reach the market through 510(k) clearance, which establishes substantial equivalence to an existing product rather than approving a particular design. In Medtronic v. Lohr, 518 U.S. 470 (1996), the Court held that 510(k) clearance does not impose device-specific federal requirements and so does not preempt state design or warning claims. Many metal-on-metal hip systems and similar products entered the market this way, which is why their litigation has proceeded on ordinary Georgia defect theories while premarket-approved devices have not.

FDA pathway Typical preemption result
Premarket approval (Class III) Design and warning claims preempted (Riegel); parallel violation claims may survive
510(k) clearance State design and warning claims not preempted (Lohr)
Either pathway, fraud-on-FDA only Impliedly preempted (Buckman)

Reading a Hip or Cardiac Failure Through This Lens

The pathway question reframes how a specific failure is analyzed. A fractured pacemaker lead on a premarket-approved device usually pushes a claimant toward a manufacturing-defect or federal-requirement-violation theory rather than a design attack on the approved configuration. A metal-on-metal hip cleared under 510(k) leaves design and warning theories about wear debris and metallosis available under state law. Evidence is concrete in either posture: the explanted device itself, retrieved and preserved at revision surgery, becomes central proof, and engineering and medical experts connect the physical failure to the injury. A device discarded after removal can forfeit the strongest evidence of what went wrong.

Medical-Damages Proof in a Device Case

Georgia’s 2025 tort-reform statute, Senate Bill 68, did not change product or preemption law, but for claims arising on or after April 21, 2025 it altered medical-damages proof. Under OCGA 51-12-1.1 recoverable medical specials are limited to the reasonable value of necessary care, and both billed charges and amounts actually paid are admissible, which can move the recoverable figure for revision surgeries and follow-up care toward the paid amount rather than the sticker bill. If a damages phase is reached in a device case meeting the threshold, SB 68 also permits either party to request a bifurcated trial separating fault from damages, a procedure addressed in the trial discussions referenced elsewhere. Apportionment of fault among manufacturer, hospital, surgeon, or component supplier follows OCGA 51-12-33, the comparative-fault rule whose full operation is owned by the 50%-bar discussion. The general rule that ordinary personal-injury non-economic damages carry no statutory cap, the medical-malpractice cap having been struck in Atlanta Oculoplastic Surgery v. Nestlehutt, is addressed in the damages discussions and not restated here.

Ten-Year Repose Running From First Sale

A short timeline shows how the repose period can operate. Suppose a hip system is first sold as new in 2012, implanted that year, and the wear injury becomes apparent in 2024. The ten-year repose under OCGA 51-1-11 runs from first sale of the unit, so by 2024 the repose window may have closed for a pure design claim, while the statutory duty-to-warn exception can keep a claim alive where the manufacturer learned of the danger after sale and failed to warn. The dates illustrate the repose and exception mechanics only and predict nothing about any actual claim.

Frequently Asked Questions

Does FDA approval block all Georgia claims over a defective device?
No. Premarket approval preempts claims that a device should have been designed or labeled differently than the FDA approved (Riegel), but claims that the manufacturer violated the federal requirements themselves can proceed as parallel claims, and devices cleared through 510(k) are not subject to that preemption (Lohr).

What is the difference between PMA and 510(k) for liability?
Premarket approval reviews and imposes requirements on a specific design, triggering preemption of conflicting state claims, while 510(k) clearance only finds the device equivalent to an existing one and does not impose device-specific federal requirements, so state design and warning claims remain available.

How long after implantation can a Georgia device claim be brought?
OCGA 51-1-11 sets a ten-year statute of repose running from the first sale of the unit, subject to a duty-to-warn exception when the manufacturer learned of a danger after sale; the separate two-year limitations period for the injury runs from when the injury and its cause were or should have been discovered.

Why does the explanted device matter so much?
The removed device is often the clearest physical evidence of a manufacturing or design defect, and engineering testing of the preserved unit can establish what failed; a discarded device can eliminate that proof.

  • Georgia product-liability statute, strict liability, ten-year repose, and duty-to-warn exception, OCGA 51-1-11
  • Premarket-approval preemption, Riegel v. Medtronic, Inc., 552 U.S. 312 (2008)
  • 510(k) clearance does not preempt state claims, Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996)
  • Implied preemption of fraud-on-the-FDA claims, Buckman Co. v. Plaintiffs’ Legal Committee, 531 U.S. 341 (2001)
  • Reasonable-value medical special damages, Senate Bill 68 (2025), OCGA 51-12-1.1 (claims arising on or after April 21, 2025)
  • Apportionment of fault, OCGA 51-12-33, addressed in the comparative-negligence discussion
  • No general cap on non-economic damages; med-mal cap struck in Atlanta Oculoplastic Surgery, P.C. v. Nestlehutt, 286 Ga. 731 (2010), referenced in the damages discussions

Disclaimer

This article provides general information about defective medical device claims under Georgia and federal law. It is not legal advice, does not create an attorney-client relationship, and may not reflect the most recent legal developments. How preemption and product-liability rules apply depends on the FDA pathway, the device records, and the specific facts. A person dealing with a Georgia medical-device injury matter should consult a licensed Georgia attorney about their particular situation.